CMS advises Bruker on its investment in Navignostics

The US tech company Bruker Corporation has invested in Navignostics. Bruker, a NASDAQ-listed company working in the analytical instrumentation sector, led the CHF 7.5 million seed financing round, which was also joined by Think.Health Ventures, Ventura Biomed Investors and Zürcher Kantonalbank.

Founded in 2022, Navignostics strives to support the selection of targeted and immuno-oncology therapies tailored to the tumour phenotype of individual cancer patients by using artificial intelligence driven software combined with single-cell resolved spatial proteomic tumour data. The spin-off from the University of Zurich uses AI driven software, coupled to single-cell resolved spatial proteomic tumor data to identify the best possible treatment for each cancer patient.

The funding will strengthen the company’s ability to collaborate with clinical, biotechnology and pharmaceutical partners and accelerate the development of its first diagnostic product.

CMS Switzerland advised Bruker on all legal matters of the transaction. The team was led by partner Stefan Brunnschweiler (corporate/m&a, pictured), Pascal Stocker (ssociate, corporate/m&a), Simone Brauchbar Birkhäuser (counsel, intellectual property), Hadi Mirzai (associate, life sciences and competition).

Sarah Keller, Associate, Employment